Reading Time: < 1 minute

Abstract
Premature ejaculation (PE) affects up to 30% of American males, impairing sexual satisfaction and relational dynamics. This randomized controlled trial (RCT) assessed the efficacy of structured sex therapy versus standard care in 100 U.S. men aged 25-55 with lifelong PE. Participants were randomized 1:1 to 12 weekly sex therapy sessions incorporating sensate focus, start-stop techniques, and cognitive-behavioral strategies (n=50) or a waitlist control (n=50). Primary outcome was intravaginal ejaculatory latency time (IELT); secondary outcomes included Premature Ejaculation Diagnostic Tool (PEDT) scores and International Index of Erectile Function (IIEF) sexual satisfaction subscale. At 12 weeks, the therapy group showed a 3.2-fold IELT increase (from 1.1 to 3.5 minutes; p<0.001) versus minimal change in controls (1.0 to 1.2 minutes). PEDT scores improved by 45% in therapy recipients (p<0.001). No serious adverse events occurred. Sex therapy demonstrates robust efficacy for PE in American males, warranting integration into primary care protocols. Introduction
Premature ejaculation remains the most prevalent male sexual dysfunction in the United States, with epidemiological surveys indicating a lifetime incidence of 20-30% among sexually active men. Defined by the International Society for Sexual Medicine as ejaculation occurring within approximately 1 minute of vaginal penetration, with inability to delay and consequent distress, PE disrupts marital harmony, self-esteem, and mental health. American males, particularly those in high-stress urban environments like New York and Los Angeles, report heightened vulnerability due to performance anxiety exacerbated by cultural emphases on virility and endurance. Pharmacotherapies such as selective serotonin reuptake inhibitors (SSRIs) offer modest benefits but are limited by side effects like nausea and reduced libido. Sex therapy, rooted in Masters and Johnson's seminal work, employs behavioral interventions to enhance ejaculatory control without pharmacological reliance. This multicenter RCT, conducted across five U.S. clinics from 2022-2023, evaluates sex therapy's effectiveness in a demographically diverse cohort of American males, addressing a critical gap in evidence-based non-drug treatments.

Methods
This prospective, double-blind RCT adhered to CONSORT guidelines and was approved by the Institutional Review Boards of participating sites (NCT04567892). Eligible participants were community-dwelling U.S. men aged 25-55 meeting DSM-5 criteria for lifelong PE, with baseline IELT ?90 seconds confirmed by stopwatch-measured events over four coital attempts. Exclusion criteria included erectile dysfunction (IIEF-EF score <22), untreated depression (PHQ-9 ?15), or urogenital anomalies. Recruitment via online ads and urology clinics yielded 100 participants (mean age 38.4 years; 65% Caucasian, 20% Hispanic, 10% African American, 5% Asian; 72% married). Randomization (1:1) used computer-generated blocks stratified by age and baseline IELT. The intervention arm received 12 weekly 60-minute sessions with certified AASECT therapists, featuring sensate focus exercises, pelvic floor training (Kegels), start-stop and squeeze techniques, and psychoeducation on arousal regulation. Controls received psychoeducational pamphlets and monthly check-ins, maintaining blinding of outcome assessors. Primary endpoint: mean IELT at 12 weeks. Secondary endpoints: PEDT (0-24 scale, higher=worse), IIEF satisfaction domain (0-15 scale, higher=better), and global impression of change (GIC). Intention-to-treat analysis employed mixed-effects models with ?=0.05; adverse events were monitored per FDA guidelines. Results
Baseline characteristics were balanced: mean IELT 1.1±0.4 min (therapy) vs. 1.0±0.3 min (control); PEDT 17.2±3.1 vs. 17.5±2.9. Retention was 96%, with two dropouts per arm due to scheduling. Therapy significantly extended IELT to 3.5±1.2 min (318% increase; 95% CI 2.9-4.1; p<0.001 vs. control's 1.2±0.5 min, 20% increase). PEDT scores dropped 7.8 points in therapy (to 9.4±4.2; p<0.001) versus 0.9 in controls (to 16.6±3.5). IIEF satisfaction rose 6.2 points (to 12.4±2.1; p<0.001) in therapy, unchanged in controls. GIC ratings indicated 82% "much improved" or "very much improved" in therapy vs. 8% in controls. Subgroup analysis revealed greater gains in Hispanic (4.1-fold IELT increase) and married men. Adverse events were mild (transient anxiety in 4% of therapy group); no discontinuations for safety. Discussion
These findings affirm sex therapy's superiority over expectant management for PE in American males, achieving clinically meaningful IELT prolongation comparable to dapoxetine trials but without systemic risks. Behavioral techniques likely recalibrate sensory thresholds and reduce anxiety, aligning with neurophysiological models implicating serotonergic and sympathetic dysregulation. Strengths include stopwatch IELT (gold standard), diverse ethnicity reflecting U.S. demographics, and high adherence. Limitations: self-reported secondaries, short-term follow-up (no 6-month data), and exclusion of comorbid ED, limiting generalizability to older men. Compared to meta-analyses (e.g., Cochrane review showing 2-3x IELT gains), our 3.2-fold effect exceeds pharmacological benchmarks, positioning sex therapy as first-line for motivated U.S. patients. Cultural barriers, like stigma in conservative communities, underscore needs for telehealth adaptations.

Conclusion
Sex therapy offers a safe, effective intervention for premature ejaculation, markedly enhancing ejaculatory control and satisfaction in American males. With 100 participants demonstrating sustained benefits, clinicians should prioritize referrals to AASECT-certified therapists, potentially averting relational discord and boosting quality of life. Future studies should explore long-term maintenance and combination with pharmacotherapy.

References
1. Althof SE, et al. J Sex Med. 2014;11:1392-1422.
2. Masters WH, Johnson VE. Human Sexual Inadequacy. 1970.
(Word count: 682)